Gemtuzumab Side Effects
Medically reviewed by Drugs.com. Last updated on Oct 28, 2023.
Applies to gemtuzumab: intravenous powder for solution.
Warning
Intravenous route (Powder for Solution)
Should only be used as single agent chemotherapy and not in combination chemotherapy regimens outside clinical trials. Severe myelosuppression occurs when gemtuzumab is used at recommended doses. Severe hypersensitivity reactions (including anaphylaxis), and other infusion-related reactions which may include severe pulmonary events have occurred with therapy. Some of these hypersensitivity reactions have been fatal. Patients with high peripheral blast counts may be at greater risk for pulmonary events and tumor lysis syndrome; physicians should consider leukoreduction with hydroxyurea or leukapheresis to reduce the peripheral white count to below 30,000/ microliters prior to administration of gemtuzumab. Hepatotoxicity, including severe hepatic veno-occlusive disease (VOD), has been reported with therapy. Physicians should monitor their patients carefully for symptoms of hepatotoxicity, particularly VOD.
Serious side effects of Gemtuzumab
Along with its needed effects, gemtuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking gemtuzumab:
More common
- Black, tarry stools
- bloating or swelling of the face, arms, hands, lower legs, or feet
- blood in the stools or urine
- bluish color of the fingernails, lips, skin, palms, or nailbeds
- blurred vision
- burning or stinging of the skin
- chest pain
- chills
- confusion
- convulsions (seizures)
- cough or hoarseness
- cracked lips
- decrease or increase in urine
- diarrhea
- difficulty with swallowing
- dizziness
- dry mouth
- excessive sweating
- fainting
- fast or slow heartbeat
- fever
- flushed, dry skin
- fruit-like breath odor
- headache, sudden and severe
- heavy, nonmenstrual vaginal bleeding
- inability to speak
- increased thirst or hunger
- irregular heartbeat
- large, flat, blue, or purplish patches in the skin
- lightheadedness
- lower back, joint, or side pain
- loss of appetite
- mood changes
- muscle pain or cramps
- muscle trembling or twitching
- nausea or vomiting
- numbness or tingling in the hands, feet, or lips
- pain, difficulty, or burning while urinating
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- pale skin
- palpitations
- persistent bleeding or oozing from puncture sites, mouth, or nose
- pinpoint red spots on the skin
- pounding in the ears
- rapid, shallow breathing
- rapid weight gain
- red or purplish patches or spots on the skin
- severe or continuing dull nervousness
- shortness of breath
- slurred speech
- small red or purple spots on the skin
- sneezing
- sore throat
- sores, ulcers, or white spots on the lips, tongue, or inside the mouth
- stomachache
- sweating
- swelling or inflammation of the mouth, face, fingers, feet, or lower legs
- swollen glands
- temporary blindness
- tightness in the chest
- tingling of the hands or feet
- troubled breathing, exertional
- unexplained nosebleeds
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- weakness in the arm or leg on one side of the body, sudden and severe
- wheezing
- yellow eyes or skin
Other side effects of Gemtuzumab
Some side effects of gemtuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Acid or sour stomach
- belching
- difficulty with moving
- dry, red, hot, or irritated skin
- full or bloated feeling or pressure in the stomach
- heartburn
- indigestion
- lack or loss of strength
- muscle pain or stiffness
- pain, swelling, or redness in the joints
- runny, stuffy nose
- stomach discomfort upset
- swelling of the abdominal or stomach area
- trouble with sleeping
For Healthcare Professionals
Applies to gemtuzumab: intravenous powder for injection.
Hematologic
Very common (10% or more): Bleeding (25%), thrombocytopenia (24%), febrile neutropenia (18%)
Common (1% to 10%): Hemorrhage
Frequency not reported: Myelosuppression, anemia[Ref]
Other
Very common (10% or more): Fever (79%), fatigue (46%)
Common (1% to 10%): Pain
Frequency not reported: Chills[Ref]
Gastrointestinal
Very common (10% or more): Nausea (21%), vomiting (21%), constipation (21%), mucositis (21%)
Common (1% to 10%): Diarrhea
Postmarketing reports: Neutropenic colitis (sometimes fatal)[Ref]
Respiratory
Common (1% to 10%): Pneumonia, lung edema
Frequency not reported: Hypoxia, respiratory failure, dyspnea
Postmarketing reports: Fungal lung infections (including Pulmonary mycosis and Pneumocystis jirovecii pneumonia) (sometimes fatal), interstitial pneumonia (sometimes fatal)[Ref]
Hepatic
Very common (10% or more): Increased AST (40%), increased ALT (16%)
Common (1% to 10%): Veno-occlusive liver disease (VOD) (sometimes fatal), hyperbilirubinemia[Ref]
Genitourinary
Postmarketing reports: Hemorrhagic cystitis (sometimes fatal)
Genitourinary side effects have included vaginal hemorrhage (12%) and hematuria (10%)[Ref]
Immunologic
Very common (10% or more): Infection (44%), sepsis (32%)
Postmarketing reports: Bacterial infections (including Stenotrophomonas infection), potential for immunogenicity[Ref]
Renal
Frequency not reported: Renal failure secondary to tumor lysis syndrome[Ref]
Cardiovascular
Common (1% to 10%): Tachycardia
Frequency not reported: QT interval prolongation, hypotension[Ref]
Dermatologic
Very common (10% or more): Rash (16%)[Ref]
Nervous system
Very common (10% or more): Headache (19%)[Ref]
Metabolic
Very common (10% or more): Hypophosphatemia (64%), hypokalemia (57%), hyponatremia (44%), alkaline phosphatase increased (13%), aspartate aminotransferase increased (14%), alanine aminotransferase increased (10%)
Common (1% to 10%): Blood bilirubin increased[Ref]
Hypersensitivity
Frequency not reported: Hypersensitivity (including anaphylaxis)[Ref]
More about gemtuzumab
- Check interactions
- Compare alternatives
- Reviews (2)
- Dosage information
- During pregnancy
- Drug class: CD33 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Mylotarg (gemtuzumab ozogamicin). Wyeth-Ayerst Laboratories. PROD.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.